Sona Nanotech Inc SNANF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.26
- Day Range
- $0.22–0.22
- 52-Week Range
- $0.19–0.59
- Bid/Ask
- $0.17 / $1.33
- Shares Outstanding
- 122.80M
- Market Cap
- $25.29M
- Volume/Avg
- 189 / 17,926
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Sona Nanotech Inc is involved in the nanotechnology life sciences industry. It has developed two proprietary methods for the manufacture of rod-shaped gold nanoparticles and is engaged in the research and development of its proprietary technology for use in biomedical applications and multiplex diagnostic testing platforms. The company is using its gold nano rods manufacturing technology to develop new products and methods for cancer treatment, including a Targeted Hyperthermia Therapy (THT). Additionally, it has filed patent applications in the U.S. regarding a gold nanorod conjugation concept for targeted drug delivery, combination therapies for treating cancer, and for an endoscope with an optical fibre and thermal sensor for photothermal therapy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 8
- Website
- https://www.sonanano.com
Valuation
|
Metric
|
SNANF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SNANF
|
|---|---|
Quick Ratio | 0.04 |
Current Ratio | 0.04 |
Interest Coverage | −81.93 |
Quick Ratio
SNANF
Profitability
|
Metric
|
SNANF
|
|---|---|
Return on Assets (Normalized) | −196.41% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
SNANF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|B?#bpC | LOCK|P#D?h | $129B | |||
| Moderna Inc
MRNA
| LOCK|&Gy>Y#& | LOCK|!R | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|!$dTLLV | LOCK|%<bz | $77B | |||
| argenx SE ADR
ARGX
| LOCK|!%<>SS | LOCK|Q$ | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|cLk&?Qd | LOCK|rg | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|#czzvn& | LOCK|Mnv? | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|s#g>!Tw | LOCK|xw?<y | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|yy&mj%d | LOCK|<p | $24B | |||
| Incyte Corp
INCY
| LOCK|W?rxt% | LOCK|@%% | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|Z^jT^& | LOCK|^L | $14B |
United States